3.80
—
Close of 27 Oct 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Wuhan YZY Biopharma Co
Its shares trade on HKEX under the ticker 2496.HK. It has been listed since 25 September 2023. In the fiscal year to 31 December 2025, it reported revenue of CN¥75.9m and a net loss of CN¥96.1m. At that date it held total assets of CN¥203.9m and shareholders' equity of −CN¥61.8m.
Wuhan YZY Biopharma Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Wuhan, Hubei. The company went IPO on 2023-09-25. Wuhan YZY Biopharma Co Ltd is a China-based company principally engaged in the research, development, production and sales of pharmaceuticals. The firm is mainly engaged in the research, development and industrialization of bispecific antibody drugs. The firm's main products include anti-PD1&anti-CD3, anti-CD19&anti-CD3, and anti-CDX&CD3. The firm's drug products are mainly used in major diseases such as tumor, immunity, inflammation, cardiovascular and infection.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 25 Sept 2023
- Website
- yzybio.com ↗
Leadership
Pay as last reported
- Mr. Pengfei ZhouChairman of the Board, Chief Executive Officer, Co-Founder, General Manager
- Mr. Jizu YiSenior Vice President - Quality
- Mr. Bin YangVice President - Production Center
- Mr. Shaoyi HuangSenior Director of Clinical Department
- Mr. Jing ZhangSenior Director of R&D Center
- Mr. Zhicheng WenNon-Executive Director
- Dr. Bin ChenIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Wuhan YZY Biopharma focuses on bispecific antibody drugs for tumor treatment in China.
- The company's main products target anti-PD1&anti-CD3 and anti-CD19&anti-CD3 for cancer therapy.
- Wuhan YZY Biopharma's research in bispecific antibodies addresses major diseases like inflammation and cardiovascular issues.
Weaknesses
- The company's IPO on 25 September 2023 indicates limited market history in biotechnology.
- Wuhan YZY Biopharma's focus on bispecific antibodies may face competition in the Chinese pharmaceutical market.
- The firm's reliance on a narrow product range for bispecific antibodies could limit growth opportunities.
Opportunities
- The growing demand for bispecific antibodies in China's healthcare sector presents expansion potential.
- Wuhan YZY Biopharma can leverage its research in anti-CDX&CD3 for new therapeutic applications.
- Increasing investment in biotechnology in China supports the company's growth in the health care industry.
Threats
- Regulatory changes in China's biotechnology sector could impact the company's operations.
- Competition from established pharmaceutical firms in the Chinese market poses a risk.
- Global economic downturns might affect funding for biotechnology research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.